PATH is a partnership that includes the Office of the Vice President for Research (OVPR), the School of Pharmacy, and the School of Medicine to accelerate the translational pathway for researchers to convert their discoveries to new medical therapeutics. Under PATH, funding will be provided to academic research programs designed to quickly develop novel therapeutic approaches focusing on well validated molecular targets for a specific disease areas with an unmet treatment need in the current commercial marketplace. Projects focusing on a wide range of therapeutic interventions (small molecule, biologic, antibody, peptide, gene therapy) are eligible for consideration. Projects related to medical diagnostics, medical devices, and digital health are not eligible. Two levels of funding will be available through this mechanism: PATH Trailblazer Grants will provide up to $10K for preliminary work in support of treatment development while PATH Ascent Grants will provide $75K-$150K to accelerate the development of promising therapeutics.

To learn more about the program, visit the OVPR Storrs site.